Merck Sharp + Dohme Corp.

Keith Rosauer

John E Stelmach

Emma R Parmee

James R Tata

Subharekha Raghavan

Linda Brockunier

Jiang Chang

Jian Guo

Ronald M Kim

Darby Schmidt

Christopher Joseph Sinz

Jonathan A Groeper

Amy R Bittner

Hong Shen

Sherman Tim Waddell

Fa-Xiang Ding

Rui Liang

Cameron James Smith

Shouwu Miao

Xibin Liao

Yi-Heng Chen

Hong Li

Alan Whitehead

Joie Garfunkle

Olga Ornoski

Xiaoqing Han

John Stelmach

Olga A Ornoski

Darby Rye Schmidt

Linda L Brockunier

A compound of Formula (I): or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate ('cGMP') and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula (I) or a pharmaceutically acceptable salt thereof. 

Soluble guanylate cyclase activators

The invention relates to compounds having the structure of Formula (I) and pharmaceutically acceptable salts thereof, which are soluble guanylate cyclase activators. The compounds are capable of modulating the body's production of cyclic guanosine monophosphate ('cGMP') and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver. 

Compounds of Formula I are capable of modulating the body's production of cyclic guanosine monophosphate ('cGMP') and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of the Formula I, to their use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of the Formula I. 

Substituted aryl and heteroaryl derivatives are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.

Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use

Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.

Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use

Growing community of inventors

Laurence Harbor, NJ, United States of America

Keith Rosauer